EBR Systems, Inc. is a cardiac technology company focused on advancing cardiac rhythm management and helping physicians address the needs of patients requiring cardiac resynchronization therapy (CRT). Its flagship product, the WiSE® System, is described as the only leadless left ventricular endocardial pacing (LVEP) device. Designed to overcome limitations of conventional CRT, it uses ultrasonic energy to generate an electrical pacing pulse and can work with a range of existing pacing devices through an open-platform approach. Its compact, leadless design avoids the constraints of traditional lead-based pacing systems.

EBR Systems supports clinicians and the wider healthcare community with information about the WiSE System, including clinical evidence, educational resources, and safety and usage information. The company also reports on post-approval research, including the WiSE-UP study, which gathers real-world evidence from commercially treated patients. Its website provides investor information, news, career opportunities, and access to product resources. EBR Systems states that it puts patients first and values positivity, leadership, constructive expression, and the growth of its team as it develops technologies for cardiac care.